Opus Genetics Inc
Company Profile
Business description
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
Contact
8 Davis Drive
Suite 220
DurhamNC27709
USAT: +1 984 884-6030
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
18
Stocks News & Analysis
stocks
Chart of the Week: AI proving a threat to company moats
stocks
ASX coal miners will benefit from higher prices
stocks
Nvidia earnings: Another stellar quarter with no signs of a slowdown
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,699.70 | 12.10 | -0.14% |
| CAC 40 | 7,969.88 | 4.61 | -0.06% |
| DAX 40 | 23,502.25 | 228.67 | -0.96% |
| Dow JONES (US) | 46,199.62 | 793.64 | -1.69% |
| FTSE 100 | 10,305.29 | 98.31 | -0.94% |
| HKSE | 25,593.03 | 432.39 | -1.66% |
| NASDAQ | 22,164.37 | 315.16 | -1.40% |
| Nikkei 225 | 53,655.75 | 1,583.65 | -2.87% |
| NZX 50 Index | 13,070.50 | 111.73 | -0.85% |
| S&P 500 | 6,626.82 | 89.27 | -1.33% |
| S&P/ASX 200 | 8,507.00 | 1.60 | 0.02% |
| SSE Composite Index | 4,024.23 | 38.75 | -0.95% |